Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
about
Farnesylation or geranylgeranylation? Efficient assays for testing protein prenylation in vitro and in vivoDifferential requirement of CAAX-mediated posttranslational processing for Rheb localization and signalingA small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.Porcine Liver Carboxylesterase Requires Polyisoprenylation for High Affinity Binding to Cysteinyl Substrates.Combinatorial modulation of protein prenylationTLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling.Anti-inflammatory and anti-bacterial properties of tetramethylhexadecenyl succinyl cysteine (TSC): a skin-protecting cosmetic functional ingredient.Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer TherapyPrenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsQuantitative structure-activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase.Oncogenic Ras in tumour progression and metastasis.Multiple post-translational modifications affect heterologous protein synthesis.Synthesis of Farnesol Analogues Containing Triazoles in Place of Isoprenes through 'Click Chemistry'Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.Highly porous drug-eluting structures: from wound dressings to stents and scaffolds for tissue regenerationInhibition of polyisoprenylated methylated protein methyl esterase by synthetic musks induces cell degeneration.Solid-phase synthesis of prenylcysteine analogsRole of isoprenylcysteine carboxylmethyltransferase-catalyzed methylation in Rho function and migration.Salirasib in the treatment of pancreatic cancer.Tubulin, actin and heterotrimeric G proteins: coordination of signaling and structure.Synthesis and evaluation of 3- and 7-substituted geranylgeranyl pyrophosphate analogs.N-Acetylglutaminoyl-S-farnesyl-L-cysteine (SIG-1191): an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes.Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth.Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry.In vitro and clinical evaluation of SIG1273: a cosmetic functional ingredient with a broad spectrum of anti-aging and antioxidant activities.The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells.Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins.Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization.
P2860
Q33235032-8336F603-9922-4E3C-9A10-74A8AB613A71Q33604076-6E111886-3075-491C-86E2-4BEE602FE74AQ33934228-21B47FAE-EB00-4780-BAEC-AF16C793F8E8Q34006187-E9C2F4EE-0654-4231-8D71-90DE1ABB2E3DQ34071002-CB86834B-9323-4CFB-8A26-2DCB51FC0933Q34344787-42FB0200-72B0-43EA-B972-626ED44A38D1Q34440518-0B848068-7CF4-4AD6-A064-B3D3F51A2CA6Q34971882-F1A6ECCC-2FD9-46F7-AD7D-1A310AD3C60BQ35043887-FD198BA6-CF69-4CED-8FEB-4680F73FDDCDQ35928477-2F309BB1-50F8-488B-BDA5-3A835B0D4F50Q36103287-D20A3A84-2941-498D-9AFE-D178356AEBAFQ36137487-5602CBDE-453E-4FC4-A0ED-505149417A49Q36361721-2F3F0A53-034E-4844-A764-82E406FF5C02Q36537788-C86E5EB1-AC2A-4FA4-B8B1-2BB943A94AC1Q36597457-4A28654F-B960-43E6-AD4D-C3E562C574A1Q36844098-93033B51-F269-4C55-8805-72CAE5B42ABDQ37243140-3455C156-3F8F-4159-AA25-59A721808F83Q37459898-D53B09D6-1A8C-47B8-B7B9-D3F3ABE5D964Q37763095-1875E1D9-3619-41DB-AABB-C29B5662ACC1Q38144624-953CD2A1-E2DB-4C84-9431-162CF987A09CQ38291087-C1E3A65A-0DF6-49EB-BE9D-01A34646988DQ39091745-C1029F95-35E1-4EC5-AEFE-B38ABD23F8E2Q39951891-952D9513-1174-4DC0-9160-6899F888A180Q39960579-335CDA25-E1FE-45C3-A730-91C8F4334E1EQ40120482-6A9A1D78-2E18-4DD5-A714-CA00B25A93C3Q40210019-675241C2-F054-4F86-8E16-B079DD785A21Q40954990-7BB8897E-C701-42DF-BDF8-90651160F65CQ41898753-C5AF6413-2E02-4092-9D8A-CEE59E8A7DCBQ42818368-8F97E2A9-B243-4ED4-8CCD-5F4664C8D5E7
P2860
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@ast
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@en
type
label
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@ast
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@en
prefLabel
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@ast
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@en
P1476
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
@en
P2093
Adrienne D Cox
Yoel Kloog
P304
P356
10.1016/J.SEMCANCER.2004.04.004
P577
2004-08-01T00:00:00Z